-+ 0.00%
-+ 0.00%
-+ 0.00%

Chemours (CC) On Results And Data Center Push Has Value Back In Focus

Simply Wall St·08/13/2026 13:34:49
Listen to the news

Chemours (CC) has been in focus after a cluster of updates that matter for stockholders. The company reported fresh quarterly results, issued guidance, affirmed its dividend, and launched new low GWP refrigerants for data center cooling.

See our latest analysis for Chemours.

Chemours shares trade at US$15.24 after a recent 1-day share price return of 2.97% and 7-day share price return of 4.46%, although the 90-day share price return is down 38.70%, while the 5-year total shareholder return has fallen 45.76%. This suggests recent momentum is trying to rebuild against a weaker longer history as investors weigh new Opteon data center products, cautious guidance, and ongoing portfolio reviews.

If Chemours' push into data center cooling has your attention, it can also be useful to see what else is moving in adjacent infrastructure. Take a look at the 36 power grid technology and infrastructure stocks

Chemours is trading well below many analysts’ implied value while it still reports losses and faces softer demand in parts of the portfolio. Does that mix of discount, pressure, and data center optionality still favor buyers?

Most Popular Narrative: 38.2% Undervalued

The most followed Chemours valuation narrative sees fair value at $24.67, well above the last close of $15.24, and ties that gap to a mix of growth projects and legal clean up.

Secular demand growth for advanced materials tied to electrification, renewables, data centers, and energy storage is generating incremental sales in higher-value applications for APM; ongoing portfolio optimization and pricing improvements in these segments are structurally enhancing net margins and improving earnings quality.

Read the complete narrative.

Curious what sits behind that $24.67 fair value for Chemours? The story leans heavily on rising earnings power, wider margins, and a much richer profit profile than today.

Result: Fair Value of $24.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Chemours still faces material PFAS litigation and regulatory costs, and any weaker TiO2 pricing or demand could quickly challenge that 38.2% undervalued narrative.

Find out about the key risks to this Chemours narrative.

Next Steps

Given the mix of concern and optimism around Chemours, it makes sense to look at the full picture and then move quickly to shape your own view using the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Chemours?

If Chemours has sharpened your thinking, do not stop here. Broaden your watchlist now so you are not relying on a single story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.